Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | STAT3 | P40763 | 1/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.36 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10552507 | 0.78 | NPSR1 (0.46) | NPSR1KDM4EHPGDSMN1; SMN2LMNA | |
| SCHEMBL1081091 | 0.78 | LMNA (0.54) | NPSR1KDM4EHPGDSMN1; SMN2LMNA | |
| SCHEMBL5433655 | 0.78 | NPSR1 (0.46) | NPSR1KDM4EHPGDSMN1; SMN2LMNA | |
| SCHEMBL2146034 | 0.78 | NPSR1 (0.46) | NPSR1KDM4EHPGDSMN1; SMN2LMNA | |
| SCHEMBL31087137 | 0.77 | NPSR1 (0.45) | NPSR1KDM4EHPGDSMN1; SMN2LMNA | |
| SCHEMBL1081092 | 0.76 | KDM4E (0.54) | NPSR1KDM4EHPGDSMN1; SMN2LMNA | |
| SCHEMBL823314 | 0.74 | ERCC1 (0.47) | NPSR1KDM4EHPGDSMN1; SMN2KDM4C | |
| SCHEMBL4962128 | 0.74 | CYP2C19 (0.43) | NPSR1KDM4EHPGDSMN1; SMN2LMNA | |
| SCHEMBL23213731 | 0.74 | KDM4E (0.45) | NPSR1KDM4ESMN1; SMN2LMNAL3MBTL1 | |
| SCHEMBL4510342 | 0.74 | NPSR1 (0.42) | NPSR1KDM4EHPGDSMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4709374-A2 | KCC2 POTENTIATORS AND USES THEREOF | Axonis Therapeutics, Inc. (US) | 2026-03-18 | — | — | EP | disclosed |
| US-20260062402-A1 | KCC2 POTENTIATORS AND USES THEREOF | AXONIS THERAPEUTICS INC (US) | 2026-03-05 | — | — | US | disclosed |
| US-20250215013-A1 | SUBSTITUTED TRICYCLIC COMPOUNDS AS PARP INHIBITORS AND THE USE THEREOF | IMPACT THERAPEUTICS (SHANGHAI), INC. (CN) | 2025-07-03 | — | — | US | disclosed |
| EP-4490161-A1 | SUBSTITUTED TRICYCLIC COMPOUNDS AS PARP INHIBITORS AND THE USE THEREOF | Impact Therapeutics (Shanghai), Inc. (CN) | 2025-01-15 | — | — | EP | disclosed |
| CN-119013279-A | Substituted tricyclic compounds as PARP inhibitors and uses thereof | 上海瑛派药业有限公司 | 2024-11-22 | — | — | CN | disclosed |
| WO-2024233885-A2 | KCC2 POTENTIATORS AND USES THEREOF | AXONIS THERAPEUTICS, INC. (US) | 2024-11-14 | — | — | WO | disclosed |
| EP-4273146-A1 | TRICYCLIC COMPOUND AND USE THEREOF | Nanjing Zaiming Pharmaceutical Co., Ltd. (CN) | 2023-11-08 | — | — | EP | disclosed |
| WO-2023169226-A1 | SUBSTITUTED TRICYCLIC COMPOUNDS AS PARP INHIBITORS AND THE USE THEREOF | Impact Therapeutics (Shanghai), Inc (CN) | 2023-09-14 | — | — | WO | disclosed |
| WO-2022143864-A1 | TRICYCLIC COMPOUND AND USE THEREOF | 江苏先声药业有限公司 | 2022-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250215013-A1 | SUBSTITUTED TRICYCLIC COMPOUNDS AS PARP INHIBITORS AND THE USE THEREOF | PARP1, PARP2, PARP3 | NPSR1 3869/4885KDM4E 1608/4885HPGD 1019/4885 |
| US-20260062402-A1 | KCC2 POTENTIATORS AND USES THEREOF | HCN2, HCN1, HCN4 | NPSR1 917/4885KDM4E 2478/4885HPGD 2024/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.